International Initiative for Harmonization of Neurofilament light chain NfL clinical reporting in neurological diseases

Archive ouverte

Delaby, Constance | Teunissen, Charlotte, E | Olsen, Dorte, Aalund | Alcolea, Daniel | Lleó, Alberto | Algeciras-Schimnich, Alicia | Santos, Gustavo, a A | Amar, Bouaziz | Ayrignac, Xavier | Baldeiras, Inês | Bigot-Corbel, Edith | Bjerke, Maria | Carretero Perez, Mercedes | Casoli, Tiziana | Chabrashvili, Tinatin | Chapman, Miles, D | Cusato, Jessica | Dursun, Erdinc | Fourier, Anthony | Galimberti, Daniela | Gezen-Ak, Duygu | Gordon, Brian, A | Hart, Melanie | Herwerth, Marina | Kaczorowski, Flora | Kasuga, Kensaku | Keshavan, Ashvini | Khalil, Michael | Koertvelyessy, Peter | Kuhle, Jens | Ladang, Aurélie | Lewczuk, Piotr | Tsolaki, Magda | Giuffrè, Guido, Maria | Blanc, Marie-Céline | Mroszko, Barbara | Musso, Giulia | Kulczynska-Przybik, Agnieszka | Nogueira, Léonor | Paquet, Claire | Parchi, Piero | Parnetti, Lucilla | Garay, Raquel, Perez | Poesen, Koen | Quadrio, Isabelle | Quillard- Muraine, Muriel | Rodriguez Borja, Enrique | Schraen, Susanna | Terracciano, Daniela | Tumani, Hayrettin | Tzartos, John | Unterwalder, Nadine | Vermunt, Lisa | Wellington, Cheryl, L | Yriarte, Jose | Blennow, Kaj | Zetterberg, Henrik

Edité par CCSD -

International audience. The quantification of neurofilament light chain (NfL) in blood and cerebrospinal fluid (CSF) has proved useful in many contexts, for the diagnosis and prognosis of various neurological disorders. There is, however, a diversity of practices between centers, essentially linked to the context of use (COU), analytical methods, consideration of comorbidities, determination of cut-points or use of interpretation scales. Finally, for the same biochemical profile, the interpretation and reporting of results may differ from one center to another, raising the question of test commutability. To date, no consensus has been reached between the different laboratories involved to define the most appropriate conclusions/comments based on COU and cut-points. This work is an essential step towards consensual harmonization of the clinical use of NfL after CSF and/or blood analysis in various neurological contexts, as advocated by the Alzheimer's Association "Biofluid Based Biomarkers PIA" working group.

Consulter en ligne

Suggestions

Du même auteur

International Initiative for Harmonization of Cerebrospinal Fluid Diagnostic comments in Alzheimer's Disease

Archive ouverte | Delaby, Constance | CCSD

International audience. The quantification of cerebrospinal fluid (CSF) biomarkers (Amyloid beta peptides [Aß1-40 and Aß1-42], tau protein and its phosphorylated form phospho-tau (ptau(181)) is progressively impleme...

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

Archive ouverte | Delaby, Constance | CCSD

International audience. Introduction: The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemi...

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Archive ouverte | Lewczuk, Piotr | CCSD

International audience. In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkersof neurodegenerative dementias, enormous advancement has taken place in the field, and theTask For...

Chargement des enrichissements...